Influence of Pluronic® F68 on Ceftazidime Biological Activity in Parenteral Solutions

β-Lactam antimicrobials are known to have a low concentration/therapeutic response. However, extending the period in which β-lactam are free in the plasma does directly influence therapeutic outcomes. The objective of this study was to evaluate the influence of Pluronic® F68 on the antimicrobial act...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2011-02, Vol.100 (2), p.715-720
Hauptverfasser: Dos Santos, Carolina Alves, Ribeiro, Gabriel Borghesan, Knirsch, Marcos Camargo, Junior, Adalberto Pessoa, Vessoni Penna, Thereza Christina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:β-Lactam antimicrobials are known to have a low concentration/therapeutic response. However, extending the period in which β-lactam are free in the plasma does directly influence therapeutic outcomes. The objective of this study was to evaluate the influence of Pluronic® F68 on the antimicrobial activity of ceftazidime when admixed with aminophylline in parenteral solutions by the evaluation of its minimal inhibitory concentration (MIC) within 24h. Ceftazidime, aminophylline, and Pluronics® F68 were evaluated using the MIC method against Escherichia coli and Pseudomonas aeruginosa, with these compounds individually and associated in the same parenteral solutions. When Pluronics® F68 was admixtured with ceftazidime alone or with ceftazidime and aminophylline, it was possible to observe lower MIC values not only at 24h but also at 0h for both microorganisms. This indicates that Pluronics® F68 may be able to enhance ceftazidime antimicrobial activity in the presence or absence of aminophylline. This fact suggests that Pluronics® F68 can be applied to allow the administration of ceftazidime under continuous infusion in parenteral solutions, beneficiating hospital pharmacotherapy. It may also be possible to reduce ceftazidime doses in formulations achieving the same therapeutic results.
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.22287